Glp-1 receptor agonists: from weight loss to comprehensive health care

1. INTRODUCTION

GLP-1 (Glucagon-Like Peptide-1) is a gut-derived hormone that plays an important role in regulating satiety, delaying gastric emptying, and stimulating glucose-dependent insulin secretion. GLP-1 receptor agonists are currently used in the treatment of type 2 diabetes and obesity. In recent years, this class of medications has attracted considerable attention in the management of obesity and metabolic disorders. Therapies such as semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) have not only improved weight-management outcomes but have also contributed to a shift in how the medical community understands and approaches obesity.

In the past, obesity was often regarded primarily as the result of excessive food intake or an unhealthy lifestyle. Today, however, a growing body of evidence recognizes obesity as a complex chronic disease influenced by multiple biological, psychological, and social factors. Hormonal regulation of hunger and satiety, insulin resistance, sleep quality, chronic stress, chronic inflammation, reproductive health, and psychological factors can all have a significant impact on an individual’s ability to regulate body weight.

2. MECHANISM OF ACTION OF GLP-1 RECEPTOR AGONISTS

Physiologically, GLP-1 is an incretin hormone secreted by intestinal L cells after food intake. However, endogenous GLP-1 is rapidly inactivated within approximately 1–2 minutes by the enzyme dipeptidyl peptidase-4 (DPP-4).

Newer GLP-1 receptor agonists (GLP-1 RAs), such as semaglutide, are structurally modified to resist degradation by DPP-4 and to increase binding to plasma albumin. These modifications prolong their elimination half-life and allow some agents to be administered once weekly.

Notably, newer molecules such as tirzepatide have a dual agonist mechanism involving both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, resulting in enhanced metabolic effects.

When these medications bind to the GLP-1 receptor (GLP-1R), a G-protein-coupled receptor (GPCR) located on the cell membrane, they activate intracellular signaling through adenylate cyclase. This increases intracellular cyclic adenosine monophosphate (cAMP) levels and activates protein kinase A (PKA), leading to several key pharmacological effects:

At the pancreas

GLP-1 receptor agonists stimulate pancreatic beta cells to increase insulin secretion in a glucose-dependent manner. In other words, insulin secretion is enhanced primarily when blood glucose levels are elevated, which helps minimize the risk of excessive hypoglycemia.

At the same time, these medications suppress glucagon secretion from pancreatic alpha cells, thereby reducing hepatic glucose production and gluconeogenesis.

In the central nervous system

GLP-1–based therapies act on the hypothalamus and the brain’s reward pathways to enhance satiety, reduce appetite and food cravings, and decrease persistent food-related thoughts and urges to eat.

In the gastrointestinal tract

These medications delay gastric emptying and reduce gastrointestinal motility, thereby prolonging the time food remains in the digestive tract and increasing postprandial fullness.

The combination of enhanced insulin secretion, suppression of glucagon, delayed gastric emptying, and regulation of eating behavior produces a dual therapeutic benefit: sustained improvement in HbA1c in patients with type 2 diabetes and meaningful reductions in excess body fat in patients with obesity.

3. OBESITY TREATMENT INVOLVES MORE THAN MEDICATION ALONE

Worldwide, nearly 40% of adults are overweight and approximately 13% are living with obesity. GLP-1–based therapies have transformed the field of weight management and may result in an average body-weight reduction of approximately 15–25% after about one year in patients with obesity.

The substantial effectiveness of GLP-1–based therapies has created new opportunities for patients with obesity. However, experts have cautioned that placing excessive emphasis on pharmacological treatment may result in insufficient attention to the underlying factors contributing to weight gain.

In clinical practice, many patients who seek obesity treatment are dealing not only with excess body weight but also with conditions such as sleep deprivation, chronic stress, emotional eating, polycystic ovary syndrome (PCOS), perimenopause, insulin resistance, anxiety, poor body image, or postpartum health changes.

Although GLP-1–based therapies can effectively reduce appetite and support weight loss, they cannot replace mental health care, nutritional counseling, or sustainable lifestyle modification. Even after successful weight loss, some patients may continue to experience difficulties adjusting to changes in body image, maintaining healthy eating behaviors, or addressing pre-existing psychological concerns.

Therefore, treatment outcomes should not be assessed solely on the basis of the number of kilograms lost. A comprehensive evaluation should also consider quality of life, mental well-being, nutritional status, physical health, and the patient’s ability to maintain the benefits of treatment over the long term.

4. CHALLENGES ASSOCIATED WITH UNSUPERVISED GLP-1 USE

As demand for GLP-1–based therapies continues to increase, there has also been a growing trend toward their use without adequate medical supervision or simply in response to social media trends.

On social media platforms, users frequently share personal experiences with these medications, discuss dosing strategies, or seek rapid weight-loss approaches without appropriate professional guidance.

Healthcare professionals emphasize that GLP-1–based medications are pharmacologically active therapies with significant physiological effects. Inappropriate use, use without proper indications, or inadequate medical monitoring may increase the risk of adverse effects.

Common gastrointestinal adverse effects include nausea, vomiting, diarrhea, and constipation. More serious complications may include gallbladder disease, including cholecystitis, and acute pancreatitis.

Therefore, appropriate prescribing, regular monitoring, and periodic clinical assessment by qualified healthcare professionals remain essential to ensure both the effectiveness and safety of treatment.

5. PATIENTS WANT MORE THAN WEIGHT LOSS

In clinical practice, patients’ expectations increasingly extend beyond weight reduction alone. Many individuals seek improvements in energy levels, sleep quality, physical function, reproductive health, self-confidence, and overall quality of life.

This is particularly relevant for women, in whom weight gain related to hormonal changes, perimenopause, PCOS, or postpartum physiological changes may occur alongside other symptoms such as fatigue, mood disturbances, and impaired quality of life.

In such cases, weight reduction represents only one component of the overall treatment goal.

Research and clinical experience suggest that listening to patients, understanding the psychological and social factors affecting their health, and developing individualized treatment plans may provide more sustainable outcomes than an approach focused exclusively on body weight.

6. THE TREND TOWARD COMPREHENSIVE METABOLIC CARE

Many experts believe that the future of obesity treatment will extend beyond conventional weight-loss services toward a more comprehensive model of metabolic care.

Within this model, GLP-1–based therapies are considered an important therapeutic tool, but not the only solution.

Effective obesity management should combine pharmacological therapy with nutritional counseling, endocrine assessment when appropriate, psychological support, optimization of sleep, preservation of muscle mass, behavioral modification, and long-term clinical follow-up.

A multidisciplinary approach can not only improve weight-related outcomes but also enhance patients’ physical health, psychological well-being, and overall quality of life.

The development of GLP-1–based therapies represents one of the major advances in modern metabolic medicine. However, their true value lies not only in their ability to promote weight loss but also in the opportunity they provide to develop a safer, more comprehensive, individualized, and sustainable approach to health care.

In the future, the goal of obesity treatment should not simply be to make patients thinner. More importantly, treatment should aim to help patients become healthier, more physically active, and better able to maintain an improved quality of life over the long term.

7. CONCLUSION

GLP-1–based therapies are creating new opportunities in the treatment of obesity and metabolic disorders. However, sustainable outcomes can only be achieved when pharmacological treatment is combined with appropriate nutrition, lifestyle modification, psychological support, and long-term medical follow-up.

The ultimate goal of treatment is not merely weight loss, but rather the improvement of overall health and quality of life.

REFERENCES

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183. Accessed July 19, 2026.
2. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414–1425. https://pubmed.ncbi.nlm.nih.gov/33755728/. Accessed July 19, 2026.
3. National Institute for Health and Care Excellence (NICE). Technology Appraisal TA875: Semaglutide for Managing Overweight and Obesity. Published March 2023; updated September 2023. https://www.nice.org.uk/guidance/ta875. Accessed July 19, 2026.
4. Halford JCG, Boyland EJ, Blundell JE, Kirkham TC, Harrold JA. Pharmacological management of appetite expression in obesity. Nat Rev Endocrinol. 2010;6(5):255–269. https://pubmed.ncbi.nlm.nih.gov/20234354/. Accessed July 19, 2026.
5. World Health Organization (WHO). Obesity and Overweight. Fact Sheet. World Health Organization; 2025. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed July 19, 2026.
6. Reiss AB, Gulkarov S, et al. Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss. Biomolecules. 2025;15(3). https://pmc.ncbi.nlm.nih.gov/articles/PMC11940170/. Accessed July 19, 2026.

Nguyen Xuan Tu, MSc

Nguyen Yen Ha, MSc